Biomarkers in Polycystic Kidney Disease: Are We There?

Adv Kidney Dis Health

Department of Epidemiology and Biostatistics, School of Public Health, Indiana University Bloomington, Bloomington, IN.

Published: May 2023

AI Article Synopsis

  • The article talks about special markers in blood and urine that help doctors understand and treat autosomal dominant polycystic kidney disease.
  • It highlights promising markers related to kidney damage and inflammation but says they aren’t better than measuring kidney size.
  • There's a program by the FDA to help approve these markers for drug development, but not enough studies have been done to find the best ones.

Article Abstract

This article describes the use of prognostic, predictive, and response biomarkers that have been developed for autosomal dominant polycystic kidney disease and their use in clinical care or drug development. We focus on biochemical markers that can be assayed in patients' blood and urine and their association with the outcome of decreased glomerular filtration rate. There have been several studies on prognostic biomarkers. The most promising ones have been markers of tubular injury, inflammation, metabolism, or the vasopressin-urinary concentration axis. So far, none have been shown to be superior to kidney volume-based biomarkers. Several biomarkers are additive to kidney volume and genotype in prognostic models, but there have been few direct comparisons between the biochemical markers to identify the best ones. Moreover, there is a lack of uniformity in the statistical tools used to assess and compare biomarkers. There have been few reports of predictive and response biomarkers, and none are suitable surrogate endpoints. The U.S. Food and Drug Administration's Biomarker Qualification Program provides a regulatory pathway to approve biomarkers for use across multiple drug-development programs.

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.akdh.2022.12.009DOI Listing

Publication Analysis

Top Keywords

biomarkers
8
polycystic kidney
8
kidney disease
8
predictive response
8
response biomarkers
8
biochemical markers
8
biomarkers polycystic
4
kidney
4
disease there?
4
there? article
4

Similar Publications

Triglyceride-independent associations between circulating levels of apolipoprotein C-III and biomarkers of inflammation.

Cardiovasc Diabetol

January 2025

Facultat de Medicina i Ciències de la Salut, Unitat de Recerca en Lípids i Arteriosclerosi, Universitat Rovira i Virgili, Reus, Spain.

Backgrounds And Aims: Preclinical studies suggest that a triglyceride (TG)-independent proinflammatory action of apolipoprotein C-III (apoCIII) exists. We aimed to investigate the relationship between circulating apoCIII levels and subclinical inflammation markers across different cohorts with distinctive inflammatory patterns: patients with metabolic disorders (MDs), patients with rheumatoid arthritis (RA), and controls. Specifically, we assessed the associations of apoCIII with acute inflammation biomarkers (e.

View Article and Find Full Text PDF

Background: As the prevalence of metabolic syndrome (MetS) rises among older adults, the associated risks of cardiovascular diseases and diabetes significantly increase, and it is closely linked to various metabolic processes in the body. Dysregulation of tryptophan (TRP) metabolism, particularly alterations in the kynurenine (KYN) and serotonin pathways, has been linked to the onset of chronic inflammation, oxidative stress, and insulin resistance, key contributors to the development of MetS. We aim to investigate the relationship between the TRP metabolites and the risk of MetS in older adults.

View Article and Find Full Text PDF

Background: Recent advancements in contemporary therapeutic approaches have increased the survival rates of lung cancer patients; however, the long-term benefits remain constrained, underscoring the pressing need for novel biomarkers. Surfactant-associated 3 (SFTA3), a long non-coding RNA predominantly expressed in normal lung epithelial cells, plays a crucial role in lung development. Nevertheless, its function in lung adenocarcinoma (LUAD) remains inadequately understood.

View Article and Find Full Text PDF

Background: Benign and malignant breast tumors differ in their microvasculature morphology and distribution. Histologic biomarkers of malignant breast tumors are also correlated with the microvasculature. There is a lack of imaging technology for evaluating the microvasculature.

View Article and Find Full Text PDF

Role of T cell metabolism in brain tumor development: a genetic and metabolic approach.

BMC Neurol

January 2025

Department of Neurosurgery, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.

Background: Malignant brain tumors are among the most lethal cancers. Recent studies emphasized the crucial involvement of the immune system, especially T cells, in driving tumor progression and influencing patient outcomes. The emerging field of immunometabolism has shown that metabolic pathways play a pivotal role in regulating immune responses within the tumor microenvironment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!